North Carolina Biotech CEOs – A Roundtable Interview With “The Pink Sheet” DAILY, Part 1
This article was originally published in The Pink Sheet Daily
CEOs from five North Carolina-based biotechs discuss the challenges present in today’s FDA approval process.
You may also be interested in...
Treximet will hit the U.S. market in mid-May, GSK says.
Pear Therapeutics’ Somryst insomnia treatment tool has become the first FDA-cleared product that was reviewed through the agency’s Software Precertification Pilot Program.
CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.